Rankings
▼
Calendar
TARS Q3 2023 Earnings — Tarsus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
TARS
Tarsus Pharmaceuticals, Inc.
$3B
Q3 2023 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$2M
Gross Profit
$1M
79.9% margin
Operating Income
-$41M
-2187.9% margin
Net Income
-$39M
-2092.4% margin
EPS (Diluted)
$-1.28
QoQ Revenue Growth
+Infinity%
Cash Flow
Operating Cash Flow
-$32M
Free Cash Flow
-$37M
Stock-Based Comp.
$5M
Balance Sheet
Total Assets
$268M
Total Liabilities
$55M
Stockholders' Equity
$214M
Cash & Equivalents
$227M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$2M
$0
—
Gross Profit
$1M
-$211,000
+808.1%
Operating Income
-$41M
-$23M
-78.7%
Net Income
-$39M
-$23M
-73.9%
Revenue Segments
Product
$2M
88%
License And Collaboration
$218,000
12%
← FY 2023
All Quarters
Q4 2023 →